Navigation Links
Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
Date:10/30/2007

CALGARY, Oct. 30 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced its financial results and highlights for the three and nine-month periods ended September 30, 2007.

Third Quarter Highlights

- Announced positive interim results from a U.K. Phase Ia/1b

combination REOLYSIN(R) and radiation trial for patients with

advanced cancers - including partial and remote responses in patients

with a variety of advanced cancers;

- Commenced patient enrolment in a multi-centre, combination

REOLYSIN(R) and docetaxel (Taxotere(R)) systemic administration trial

in the U.K.;

- In October, received approval from the U.K. regulatory authorities to

begin a combination REOLYSIN(R) and cyclophosphamide trial for

patients with advanced cancers;

- Secured two additional U.S. patents, for a total of more than 150

issued patents worldwide; and,

- Presented preclinical work at the National Cancer Research Institute

Conference in Birmingham, U.K. demonstrating for the first time how

reovirus-infected melanoma cells stimulate dendritic cells to prime

the immune system against cancer cells.

"With positive results being reported from our clinical trial program in the U.K. and the U.S., seven trials actively enrolling, an additional combination trial approved to begin and an expanding intellectual property portfolio supporting our technology, Oncolytics is looking forward to making substantial progress through the balance of 2007 and 2008," said Dr. Brad Thompson, President and CEO of Oncolytics.

Oncolytics Biotech Inc.

BALANCE SHEETS

(unaudited)

As at,

September 30, December 31,


'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related biology technology :

1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Sept. 16, 2014 In preparation for VARTECH ... -based cybersecurity company focused on authentication and SSO announced ... the ability to generate a OTP through the presentation ... pioneer of user-based RFID authentication, 2FA,s solutions have leveraged ... for many years. RFID authentication is broadly deployed in ...
(Date:9/16/2014)... Australia (PRWEB) September 16, 2014 RENU 28, ... Signaling molecules, became available for purchase in Australia and ... a nationwide tour beginning September 16th. The tour will make ... the 17th, Bundaberg on the 18th, Sydney on the 20th, ... market in Australia and New Zealand and to educate people ...
(Date:9/15/2014)... States (PRWEB) September 16, 2014 ... Cancer Vaccines, and Adoptive T-cell Therapies is a ... report focuses on the three principal types of ... research and development in cancer immunotherapy (which is ... Therapeutic anticancer vaccines and Adoptive cellular immunotherapy. ...
(Date:9/15/2014)... University have developed a technique for controlling the surface ... opening the door to a new generation of reconfigurable ... on the fact that the oxide "skin" of the ... acts as a surfactant, lowering the surface tension between ... used a liquid metal alloy of gallium and indium. ...
Breaking Biology Technology:2FA, Inc. Announces RFID-based One-Time Password (OTP) Authentication 2Global Wellness Company Hosts ASEA Australia Tour September 16-22 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5Researchers control surface tension to manipulate liquid metals 2
... , , BOULDER, Colo. and THOUSAND OAKS, Calif., Dec. 14 ... AMGN ) today announced that they entered into an agreement ... including ARRY-403, currently being tested in a Phase 1 clinical trial ... terms of the agreement, Array will receive an upfront payment of ...
... , , JUPITER, Fla., Dec. ... today that it has extended its collaboration with The Scripps ... to re-annotate the genome of Dyadic,s patented and proprietary C1 ... successful relationship between the two organizations which began in March ...
... , ROCKAWAY, N.J., Dec. 14 ... Evidence-Based Approach , published by the Infusion ... anthracycline extravasation.(1) Anthracyclines are a group of chemotherapy medications ... in the treatment of various types of cancer since the ...
Cached Biology Technology:Array BioPharma and Amgen Partner in Type 2 Diabetes 2Array BioPharma and Amgen Partner in Type 2 Diabetes 3Array BioPharma and Amgen Partner in Type 2 Diabetes 4Array BioPharma and Amgen Partner in Type 2 Diabetes 5Array BioPharma and Amgen Partner in Type 2 Diabetes 6Array BioPharma and Amgen Partner in Type 2 Diabetes 7Dyadic International Extends Collaboration With The Scripps Research Institute 2Dyadic International Extends Collaboration With The Scripps Research Institute 3Dyadic International Extends Collaboration With The Scripps Research Institute 4Dyadic International Extends Collaboration With The Scripps Research Institute 5Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 2Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 3Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 5
(Date:9/15/2014)... hearing and cognitive function may play roles in one,s ... rhythm, pitch, timbre, tone durations, and formal structure in ... article explain that extremes in musical aptitude (extreme capacity/no ... of individuals having moderate aptitude. , "This is a ... underlying genes, and it is influenced to varying degrees ...
(Date:9/15/2014)... the subsequent rapid decrease in the water level of ... square kilometres of new, fertile land in eastern Finland. ... researchers has studied the role that the decrease in ... and humans. After dramatic shifts in the waterways, human ... rise to a new, innovative culture. This stemmed from ...
(Date:9/15/2014)... Sharks, swamps and a tropical rainforest teeming with life ... Yorkshire, England. But for the first time evidence of Doncaster,s ... discovered in a derelict mining tip. , Some of the ... and as well as the egg case, several horseshoe crabs ... All had been preserved in rocks that formed within ...
Breaking Biology News(10 mins):The creation of the Vuoksi River preceded a significant cultural shift 2'Jaws' lived in Doncaster 2
... disease are increasingly becoming resistant to synthetic insecticides. Now ... Complementary and Alternative Medicine suggests that the berries of ... have potential for keeping mosquitoes at bay. S. ... for its medicinal properties and commonly used as ...
... Southern Research Station (SRS), Iowa State University, and the ... of a fungus responsible for the wilt of redbay ... Florida. In the February issue of Plant Disease, ... results from their assessment of the fungus, the beetle ...
... but the microscopic animals called bdelloid rotifers seem to get ... have done so over millions of years of evolution, resulting ... the usual drawback of asexuality extinction and the ... finding out how. In two related papers published ...
Cached Biology News:Ayurvedic nightshade deadly for dengue mosquito 2Laurel wilt of redbay and sassafras: Will avocados be next? 2Is DNA repair a substitute for sex? 2Is DNA repair a substitute for sex? 3
... for use as a wash buffer for Michels ... is useful for transportation of specimens (such as ... Samples may remain in Transport Fluid for ... Michels Transport Fluid is not a fixative and ...
... use with 96- or 384-well PCR plates Dimples ... location on 96-tube plates End tabs on Thermo-Mat™ ... plate* Efficient sealing is achieved with either Thermo-Mat™ ... or clip-down hot lid thermal cyclers Fully autoclavable ...
... TUNEL-based assay kit provides complete components including ... detection of DNA fragmentation in cultured cells ... in the procedure provides greater sensitivity than ... analyzed by flow cytometry. The kit works ...
... Buffer is a unique alternative to ... (TRIS acetate-EDTA) electrophoresis buffers. Bionic Buffer ... rapid running times, and high-resolution band ... gel electrophoresis after dilution to working ...
Biology Products: